Bleomycin-induced pulmonary toxicity and treatment with infliximab: A case report

Victor Ge; Iouri Banakh; Ravindranath Tiruvoipati; Kavi Haji

doi:10.1002/ccr3.1790

Bleomycin-induced pulmonary toxicity and treatment with infliximab: A case report

Victor Ge, Iouri Banakh, Ravindranath Tiruvoipati, Kavi Haji

Research output: Contribution to journal › Article › Other › peer-review

16 Citations (Scopus)

Abstract

Given the current understanding of bleomycin-induced pneumonitis (BIP), the use of tumor necrosis factor alpha (TNF-α) inhibitors such as infliximab for late-stage disease appears to be of limited benefit. Further research regarding prevention and management of advanced BIP is required.

Original language	English
Pages (from-to)	2011-2014
Number of pages	4
Journal	Clinical Case Reports
Volume	6
Issue number	10
DOIs	https://doi.org/10.1002/ccr3.1790
Publication status	Published - Oct 2018

Keywords

bleomycin
infliximab
intensive care
pulmonary toxicity
respiratory failure
treatment outcome

Access to Document

10.1002/ccr3.1790Licence: CC BY

Cite this

@article{cf930f8f801e47b987a7d8cd0f5a7890,

title = "Bleomycin-induced pulmonary toxicity and treatment with infliximab: A case report",

abstract = "Given the current understanding of bleomycin-induced pneumonitis (BIP), the use of tumor necrosis factor alpha (TNF-α) inhibitors such as infliximab for late-stage disease appears to be of limited benefit. Further research regarding prevention and management of advanced BIP is required.",

keywords = "bleomycin, infliximab, intensive care, pulmonary toxicity, respiratory failure, treatment outcome",

author = "Victor Ge and Iouri Banakh and Ravindranath Tiruvoipati and Kavi Haji",

year = "2018",

month = oct,

doi = "10.1002/ccr3.1790",

language = "English",

volume = "6",

pages = "2011--2014",

journal = "Clinical Case Reports",

issn = "2050-0904",

publisher = "John Wiley \& Sons",

number = "10",

}

TY - JOUR

T1 - Bleomycin-induced pulmonary toxicity and treatment with infliximab

T2 - A case report

AU - Ge, Victor

AU - Banakh, Iouri

AU - Tiruvoipati, Ravindranath

AU - Haji, Kavi

PY - 2018/10

Y1 - 2018/10

N2 - Given the current understanding of bleomycin-induced pneumonitis (BIP), the use of tumor necrosis factor alpha (TNF-α) inhibitors such as infliximab for late-stage disease appears to be of limited benefit. Further research regarding prevention and management of advanced BIP is required.

AB - Given the current understanding of bleomycin-induced pneumonitis (BIP), the use of tumor necrosis factor alpha (TNF-α) inhibitors such as infliximab for late-stage disease appears to be of limited benefit. Further research regarding prevention and management of advanced BIP is required.

KW - bleomycin

KW - infliximab

KW - intensive care

KW - pulmonary toxicity

KW - respiratory failure

KW - treatment outcome

UR - https://www.scopus.com/pages/publications/85052946690

U2 - 10.1002/ccr3.1790

DO - 10.1002/ccr3.1790

M3 - Article

C2 - 30349718

AN - SCOPUS:85052946690

SN - 2050-0904

VL - 6

SP - 2011

EP - 2014

JO - Clinical Case Reports

JF - Clinical Case Reports

IS - 10

ER -

Bleomycin-induced pulmonary toxicity and treatment with infliximab: A case report

Abstract

Keywords

Access to Document

Other files and links

Cite this